Dianthus Therapeutics to Participate in Four Investor Conferences During November

Dianthus Therapeutics to Participate in Four Investor Conferences During November

November 04, 2025 | Last Trade: US$40.04 4.54 12.79

NEW YORK and WALTHAM, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the company’s participation in four upcoming investor conferences.

Marino Garcia, CEO of Dianthus Therapeutics, will participate in fireside chats and host one-on-one investor meetings at the following conferences:

Guggenheim 2nd Annual Healthcare Innovation Conference (Boston) - Fireside chat on Tuesday, November 11, 2025 at 3:30 p.m. ET
TD Cowen Immunology & Inflammation Summit (Virtual) – Fireside chat on Wednesday, November 12, 2025 at 9:30 a.m. ET
Stifel 2025 Healthcare Conference (New York) – Fireside chat on Thursday, November 13, 2025 at 2:00 p.m. ET
Jefferies Global Healthcare Conference (London) – Corporate overview presentation on Monday, November 17, 2025 at 1.30 p.m. GMT

Webcasts of these presentations may be accessed under “News and Events” in the Investors section of the Dianthus Therapeutics website.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who aim to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.

To learn more, please visit www.dianthustx.com and follow us on LinkedIn.

Contact
Jennifer Davis Ruff
Dianthus Therapeutics
This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Last Trade:	US$40.04
Daily Change:	4.54 12.79
Daily Volume:	1,947,544
Market Cap:	US$1.720B

November 05, 2025 Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results October 29, 2025 Dianthus Therapeutics Highlights New Claseprubart Data Presented During 2025 AANEM Annual Meeting October 16, 2025 Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for Severe Autoimmune Diseases October 02, 2025 Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2025 AANEM Annual Meeting September 11, 2025 Dianthus Therapeutics Announces Closing of its Upsized $288 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares LOAD MORE NEWS

Featured Stock

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE